Brivanib

Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β.


Cat. No.: EX-A011	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	585	In-stock
250mg	985	In-stock
500mg	1385	In-stock
1g	2000	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	BMS-540215
CAS No.	649735-46-6
Purity	>98%
Formula	C19H19FN4O3
Mol Weight	370.3776
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Bhide, Rajeev S et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. Journal of medicinal chemistry vol. 49,7 (2006): 2143-6. [2]. Huynh, Hung et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research vol. 14,19 (2008): 6146-53.
CoA	CoA of Brivanib

Smiles:	C[C@@H](O)COC1=CN2N=CN=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C2=C1C


		Search